Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 862-867

  Vázquez Franco, José E ^a   Reyes Maldonado, Elba ^a   Vela Ojeda, Jorge ^a   Domínguez López, Maria L ^a   Lezama, Ruth A ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Acute lymphoblastic leukemia; Akt; Apoptosis inhibition; BCR ABL; NF B; Src

Indexed keywords

BCR ABL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW EXAMINATION; CASE-CONTROL STUDIES; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NF-KAPPA B; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION;

EID: 84862322760     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.03.020     Document Type: Article

References (45)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Jagani Z., Singh A., Khosravi-Far R. FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 2008, 1785:63-84.
3. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
4. Van Etten R.A., Shannon K.M. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 2004, 6:547-552.
5. Hu Y., Swerdlow S., Duffy T.M., Weinmann R., Lee F.Y., Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006, 103:16870-16875.
6. Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008, 49:19-26.
7. Danhauser-Riedl S., Warmuth M., Druker B.J., Emmerich B., Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996, 56:3589-3596.
8. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
9. Manning B.D., Cantley L.C. Akt/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
10. Braun T., Carvalho G., Fabre C., Grosjean J., Fenaux P., Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 2006, 13:748-758.
11. Liu P., Xu B., Li J., Lu H. LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway. Biochem Biophys Res Commun 2008, 377:187-190.
12. Kharas M.G., Deane J.A., Wong S., O'Bosky K.R., Rosenberg N., Witte O.N., et al. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 2004, 103:4268-4275.
13. Levy D.S., Kahana J.A., Kumar R. Akt inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009, 113:1723-1729.
14. Kawauchi K., Ogasawara T., Yasuyama M., Otsuka K., Yamada O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem 2009, 9:550-559.
15. Morbach H., Eichhorn E.M., Liese J.G., Girschick H.J. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol 2010, 162:271-279.
16. van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gen transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 1999, 13:1901-1928.
17. Hu Y., Liu Y., Pelletier S., Buchdunger E., Warmuth M., Fabbro D., et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004, 36:453-461.
18. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
19. Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004, 64:672-677.
20. Kharas M.G., Janes M.R., Scarfone V.M., Lilly M.B., Knight Z.A., Shokat K.M., et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008, 118:3038-3050.
21. Kucharczak J., Simmons M.J., Fan Y., Gélinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003, 22:8961-8982.
22. Gustin J.A., Ozes O.N., Akca H., Pincheira R., Mayo L.D., Li Q., et al. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem 2004, 279:1615-1620.
23. Lin C.H., Cheng H.W., Hsu M.J., Chen M.C., Lin C.C., Chen B.C. c-Src mediates thrombin-induced NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells. J Immunol 2006, 177:3427-3438.
24. Jiang X., Takahashi N., Ando K., Otsuka T., Tetsuka T., Okamoto T., et al. p65 transactivation domain is involved in the NF-kappa B-inducing kinase pathway. Biochem Biophys Res Commun 2003, 301:583-590.
25. Viatour P., Merville M.P., Bours V., Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005, 30:43-52.
26. Wilson M.B., Schreiner S.J., Choi H.J., Kamens J., Smithgall T.E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002, 21:8075-8088.
27. Meyn M.A., Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P., Wu J., et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006, 281:30907-30916.
28. Sattler M., Mohi M.G., Pride Y.B., Quinnan L.R., Malouf N.A., Podar K., et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002, 1:479-492.
29. Chen R., Kim O., Yang J., Sato K., Eisenmann K. Regulation of Akt/PKB activation by tyrosine phosphorilation. J Biol Chem 2001, 276:31858-31862.
30. Park J., Hill M.M., Hess D., Brazil D.P., Hofsteenge J., Hemmings B.A. Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity. J Biol Chem 2001, 276:37459-37471.
31. Hazlehurst L.A., Bewry N.N., Nair R.R., Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control 2009, 16:100-107.
32. Skorski T., Nieborowska-Skorska M., Campbell K., Iozzo R.V., Zon G., Darzynkiewicz Z., et al. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med 1995, 182:1645-1653.
33. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998, 12:968-981.
34. Munzert G., Kirchner D., Ottmann O., Bergmann L., Schmid R.M. Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leuk Lymphoma 2004, 45:1181-1184.
35. Kordes U., Krappmann D., Heissmeyer V., Ludwig W.D., Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000, 14:399-402.
36. Campana D., Coustan-Smith E., Manabe A., Buschle M., Raimondi S.C., Behm F.G., et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood 1993, 81:1025-1031.
37. Menendez P., Vargas A., Bueno C., Barrena S., Almeida J., De Santiago M., et al. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia 2004, 18:491-498.
38. Tolomeo M., Grimaudo S., Di Cristina A., Pipitone R.M., Dusonchet L., Meli M., et al. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. Cancer Lett 2008, 265:289-297.
39. Wen C., Ma F.T., Wan W.Q. Expression of CREB/BCL-2 in bone marrow mononuclear cells of children with acute leukemia. Zhongguo Dang Dai Er Ke Za Zhi 2010, 12:177-180.
40. Del Gaizo Moore V., Schlis K.D., Sallan S.E., Armstrong S.A., Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008, 111:2300-2309.
41. Nakagawa Y., Hasegawa M., Kurata M., Yamamoto K., Abe S., Inoue M., et al. Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL). Am J Hematol 2005, 78:173-180.
42. Tatton L., Morley G.M., Chopra R., Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. Biol Chem 2003, 278:4847-4853.
43. Alvarez R.H., Kantarjian H.M., Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006, 81:1241-1257.
44. Matsumura I., Mizuki M., Kanakura Y. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Cancer Sci 2008, 99:479-485.
45. Udomsakdi-Auewarakul C., Promsuwicha O., Tocharoentanaphol C., Munhketvit C., Pattanapanyasat K., Issaragrisil S. Immunophenotypes and outcome of Philadelphia chromosome-positive and -negative Thai adult acute lymphoblastic leukemia. Int J Hematol 2003, 78:337-343.